Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

NCT06442475 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Ann Arbor Stage II Follicular Lymphoma
Ann Arbor Stage II Marginal Zone Lymphoma
Ann Arbor Stage III Follicular Lymphoma
Ann Arbor Stage III Marginal Zone Lymphoma
Ann Arbor Stage IV Follicular Lymphoma
Ann Arbor Stage IV Marginal Zone Lymphoma
Grade 1 Follicular Lymphoma
Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Mosunetuzumab
PROCEDURE: Positron Emission Tomography
OTHER: Questionnaire Administration

Sponsor

University of Washington